CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 61 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-18 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −19,512 | $0.60 | $12K | 248,636 |
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +35,000 | 210,648 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +57,500 | 268,148 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +30,000 | 205,648 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +57,500 | 263,148 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2025-02-04 | Chu Yu-Waye Chief Medical Officer | Grant or award | +56,000 | 82,250 | ||
| 2025-02-04 | Chu Yu-Waye Chief Medical Officer | Grant or award | +57,500 | 139,750 | ||
| 2025-02-04 | Chu Yu-Waye Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +238,000 | 238,000 | ||
| 2025-02-04 | Chu Yu-Waye Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2025-02-04 | Ogden Christopher Chief Financial Officer | Grant or award | +44,000 | 152,077 | ||
| 2025-02-04 | Ogden Christopher Chief Financial Officer | Grant or award | +57,500 | 209,577 | ||
| 2025-02-04 | Ogden Christopher Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2025-02-04 | Ogden Christopher Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2025-02-04 | McCarthy Sean A. CEO | Grant or award | +180,000 | 837,851 | ||
| 2025-02-04 | McCarthy Sean A. CEO | Grant or award | +195,000 | 1,032,851 | ||
| 2025-02-04 | McCarthy Sean A. CEO | Grant or award · Stock Option (Right to Buy) | +800,000 | 800,000 |
Page 4 of 27 · 529 trades